Document is current

Any future updates will be listed below

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial

Crossref DOI link: https://doi.org/10.1038/s41392-026-02618-3

Published Online: 2026-04-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark